IDEX CORP (IEX) reported that officer Tara M. Tereso, Group Executive, HST, had 290 shares of common stock disposed of on September 16, 2026 as a payment of exercise price or tax liability by delivering or withholding securities at a price of $222.84 per share. Following this transaction, Tereso directly holds 5,408 shares of IDEX common stock, and no Rule 10b5-1 trading plan is reported.
IDEX CORP (IEX) reported that executive William L. Simmons, Group Executive, FMT & FSDP, had 218 shares of common stock disposed of on September 16, 2026 as a payment of exercise price or tax liability by delivering or withholding securities. Following this transaction, he directly holds 2,674 shares of IDEX common stock. No Rule 10b5-1 trading plan is reported.
IDEX CORP (IEX) reported that officer Tara M. Tereso, Group Executive, HST, had 138 shares of common stock delivered or withheld on September 11, 2026 for payment of exercise price or tax liability, at a recorded value of $221.46 per share. After this transaction, Tereso directly holds 5,698 common shares. No Rule 10b5-1 trading plan is reported for this transaction.
IDEX Corporation (IEX) entered into a Second Amended and Restated Credit Agreement providing a senior unsecured revolving credit facility of $800 million with a final maturity date of September 3, 2031, extending the prior facility’s November 1, 2027 final maturity date.
The facility includes up to $100 million for letters of credit and up to $50 million for same-day swingline loans, for working capital and other general corporate purposes, including refinancing existing debt. IDEX may request up to $400 million in additional commitments and, subject to conditions, may designate certain foreign subsidiaries as borrowers, whose obligations the company must guarantee.
Borrowings bear interest at a base rate or Term SOFR (or other currency reference rates) plus a margin tied to IDEX’s senior unsecured long-term debt rating or leverage ratio. The agreement permits voluntary prepayments and commitment reductions without penalty and includes customary affirmative and negative covenants, a quarterly leverage ratio test with a 12‑month step-up option for certain acquisitions, and standard events of default.
IDEX CORP (IEX) reported an insider transaction by Allison S. Lausas, Vice President and Chief Accounting Officer. On 2026-08-29, she disposed of 645 shares of common stock classified as a payment of exercise price or tax liability by delivering or withholding securities, at a reported price of $230.28 per share. Following this withholding-related disposition, she held 3,302 shares of IDEX common stock directly.
IDEX Corporation reported that on August 13, 2026, director L. Paris Watts-Stanfield resigned from its Board of Directors, effective immediately. The company stated that her resignation was not due to any disagreement regarding operations, policies, or practices. In connection with this change, the size of the Board was reduced from ten to nine directors.
IDEX Corp senior executive Lisa M. Anderson, SVP, GC, CAO & Corporate Secretary, exercised options to acquire 385 shares of common stock at an exercise price of $93.27 per share, originally granted with an exercise date of February 22, 2018 and expiring February 22, 2027. On the same day, she sold 385 shares of common stock at a weighted average price of $238.5949 per share, with individual trade prices ranging from $238.39 to $238.73. Following the transaction, the reported option position of 385 options was reduced to 0.
IDEX Corporation reported higher Q2 2026 results, with net sales of $920.6 million up 6% and net income attributable to IDEX of $143.4 million. Diluted EPS rose to $1.93, and gross margin expanded to 46.3%, helped by stronger Health & Science Technologies volumes and positive price/cost.
A U.S. Supreme Court ruling on the International Emergency Economic Powers Act led to $22.0 million of tariff refunds recorded in Cost of sales and $14.7 million of related customer rebates in Net sales, providing a net EPS benefit of $0.08. For the first half, net sales were $1,807.5 million and diluted EPS $3.54; free cash flow, a non-GAAP measure, was $263.0 million. Cash and cash equivalents totaled $621.3 million against total borrowings of $1,866.9 million, and the company returned capital through $151.3 million of share repurchases and $106.7 million of dividends while maintaining significant unused revolver capacity.
IDEX Corporation reported strong second-quarter 2026 results, with net sales of $920.6 million, up 6% year over year, and orders of $1,071.6 million, up 29%. Reported diluted EPS rose to $1.93 from $1.74, while adjusted diluted EPS increased 12% to $2.32.
Gross margin improved to 46.3% (46.4% adjusted), and adjusted EBITDA reached $258.3 million with a 28.1% margin. Operating cash flow was $200.0 million and free cash flow $177.0 million, supported by IEEPA tariff refunds. The company repurchased $77 million of stock and paid $54 million in dividends.
Management raised full‑year 2026 guidance, now expecting organic sales growth of 5–6% and adjusted diluted EPS of $8.70–$8.85. The Health & Science Technologies segment led growth, benefiting from AI-driven data center and semiconductor demand.